Novartis recently announced that it will acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company. The acquisition will add abelacimab ...
despite a mid-stage stroke trial miss – as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial ...
as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...
Zacks Investment Research on MSN4d
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of ...
In an interview with Dr. Dan Bloomfield, Cardiologist and CMO at Anthos Therapeutics, we explore the dramatic potential of abelacimab, an investigational Factor XI inhibitor currently being developed ...
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
Gretel raised more than $67 million in venture capital from investors including Anthos Capital, Greylock, and Moonshots Capital prior to its exit, according to Crunchbase. Nvidia's acquisition is ...
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback